Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | LMNA | P02545 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | XBP1 | P17861 | 1/20 | 0.74 |
| ▸ | HTT | P42858 | 1/20 | 0.74 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | FLT3 | P36888 | 2/20 | 0.53 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.53 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13066079 | 0.87 | MAPT (0.67) | MAPTNPC1LMNARAB9AKMT2A | |
| Protoapigenone SCHEMBL13066080 | 0.85 | KMT2A (1.00) | MAPTNPC1LMNARAB9AKMT2A | |
| SCHEMBL30931535 | 0.85 | PTGS1 (0.55) | MAPTNPC1LMNARAB9AKMT2A | |
| SCHEMBL30931536 | 0.85 | PTGS1 (0.55) | MAPTNPC1LMNARAB9AKMT2A | |
| SCHEMBL15395297 | 0.83 | HTT (0.76) | MAPTNPC1LMNARAB9AKMT2A | |
| SCHEMBL2874541 | 0.78 | MAPT (0.71) | MAPTNPC1LMNARAB9AKMT2A | |
| SCHEMBL13445691 | 0.75 | KMT2A (0.80) | MAPTNPC1LMNARAB9AKMT2A | |
| SCHEMBL2424752 | 0.74 | PTGS1 (0.56) | MAPTNPC1LMNARAB9AKMT2A | |
| SCHEMBL30856460 | 0.74 | IP6K2 (0.58) | MAPTNPC1LMNARAB9AKMT2A | |
| Eugenin SCHEMBL1860860 | 0.74 | PTGS1 (1.00) | MAPTNPC1LMNARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413267-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2022-08-16 | — | — | US | disclosed |
| US-20190255012-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2019-08-22 | — | — | US | disclosed |
| US-20190255012-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2019-08-22 | — | — | US | disclosed |
| EP-1980248-B1 | Composition for treating cancer cells and synthetic method for the same | UNIV KAOHSIUNG MEDICAL (TW) | 2019-06-12 | — | — | EP | disclosed |
| US-10195176-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2019-02-05 | — | — | US | disclosed |
| US-10195176-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2019-02-05 | — | — | US | disclosed |
| US-20180161303-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-06-14 | — | — | US | disclosed |
| US-20180161303-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-06-14 | — | — | US | disclosed |
| US-9918962-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-03-20 | — | — | US | disclosed |
| US-9918962-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2018-03-20 | — | — | US | disclosed |
| US-20130310448-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF ATR AND FANCD2 ACTIVATION | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2013-11-21 | — | — | US | disclosed |
| US-7842721-B2 | Composition for treating cancer cells and synthetic method for the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-30 | — | — | US | disclosed |
| US-7842721-B2 | Composition for treating cancer cells and synthetic method for the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-30 | — | — | US | disclosed |
| EP-1572197-B1 | 4- 1- (SULFONYL) -1H-INDOL-2-YL)-4- (HYDROXY) -CYCLOHEXA-2,5-DIENONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC AGENTS | CANCER REC TECH LTD (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-20090054516-A1 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-02-26 | — | — | US | disclosed |
| US-20090054516-A1 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-02-26 | — | — | US | disclosed |
| EP-1980248-A1 | Composition for treating cancer cells and synthetic method for the same | Kaohsiung Medical University (TW) | 2008-10-15 | — | — | EP | disclosed |
| EP-1980248-A1 | Composition for treating cancer cells and synthetic method for the same | Kaohsiung Medical University (TW) | 2008-10-15 | — | — | EP | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310448-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF ATR AND FANCD2 ACTIVATION | ATR, FANCD2, CHEK2 | MAPT 3776/4885NPC1 4517/4885LMNA 1248/4885 |
| US-20180161303-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | FANCD2, ATR, FANCF | MAPT 2905/4885NPC1 3757/4885LMNA 1281/4885 |
| US-20190255012-A1 | Methods and Compositions for Inhibition of ATR and FANCD2 Activation | FANCD2, ATR, FANCF | MAPT 2892/4885NPC1 3764/4885LMNA 1267/4885 |
| US-11413267-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | FANCD2, ATR, FANCF | MAPT 2892/4885NPC1 3764/4885LMNA 1267/4885 |
| US-10195176-B2 | Methods and compositions for inhibition of ATR and FANCD2 activation | FANCD2, ATR, FANCF | MAPT 2905/4885NPC1 3757/4885LMNA 1281/4885 |
| US-20090054516-A1 | COMPOSITION FOR TREATING CANCER CELLS AND SYNTHETIC METHOD FOR THE SAME | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HK2, HCCS | MAPT 4770/4885NPC1 1101/4885LMNA 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.